Table 1. Characteristics of the studies included in the network meta-analysis.
| Author, Year of publication [ref.no] |
Study period | Country | Setting | Study arms | Interventions | Participants | Male | Age, mean in year (±SD) or median and range |
PCR | Under supervision |
Funding | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rachmawati, 2010 [14] |
1/2009 - 7/2009 |
Indonesia. | H (in-pt) |
2 | AL, ASSP |
47 | 59.5% | 5.9 ±3.46 | No | Yes | Not reported |
| 2 | Ashley, 2004 [23] |
7/2002–4/2003 | Thailand | H (in-pt) |
3 | ASMQ, DHP, DHPAS | 731 | 78.1% | Adults (25.3± 8.2) |
No | Yes | Holleykin Pharmaceutical |
| 3 | Ashley, 2005 [24] |
4/ 2003–4/ 2004 | Thailand | OPD | 3 | ASMQ, DHP, DHP4 |
499 | 60.5% | Any age (21, 3–57) |
Yes | Yes | MMV; Wellcome -Mahidol;Wellcome Great Britain. |
| 4 | Kshirsaga, 2000 [25] |
6/1996–1/1997 | India | H (in-pt) |
2 | AL, CQ | 179 | 96% | 29 (17–66) |
Yes | Yes | |
| 5 | Lefevre, 2001 [26] |
9/1998-1/1999 | Thailand | H | 2 | AL, ASMQ |
219 | 70% | 50 (12–71) |
Yes | Yes | Novartis Pharma AG. |
| 6 | Huong, 2003 [27] |
NA | Vietnam | H (in-pt) |
2 | ASSP, ASCQ | 123 | 51% | Any age, 10.3 ± 11.3 (4–65) |
Yes | Yes |
male% & age in the ASSP gr |
| 7 | Silachamroon, 2005 [28] |
NA | Thailand | H (in-pt) |
2 | ASMQ, ASMQ2 | 120 | 70.8% | Adults (25.6± 10.1) |
No | Yes | WHO/RBM/ Mahidol University |
| 8 | Smithuis, 2006 [29] |
11/2003 - 4/2004 |
Myanmar | OPD | 4 | ASMQ, ASMQh, DHP, DHPh | 652 | 52% | 3 age-gr; 58.2%(5–14 yr) | Yes | Yes (Gr1 No (Gr 2) | MSF (Holland); |
| 9 | Song, 2011 [30] |
7/2005 - 10/2005 |
Cambodia | H (in-pt) |
3 | AL, AMPQ,DHP |
220 | 73% | 3 age-gr; 80% (>15 yr). | Yes | Yes | Science & Technology Planning Project, MOST/China |
| 10 | Thanh, 2009 [31] |
9/2006 - 12/2007. |
Vietnam | Health station | 2 | DHP, AMPQ |
116 | 63.8% | Any age; (20.6± 12.4) |
Yes | Yes | People’s Army Department of Military Medicine |
| 11 | Thanh, 2012 [32] |
5/2008–12/2009, | Vietnam | Commune centre | 2 | ASAQ, DHP | 128 | 70.1% | Any age; (18.9± 12.7) |
Vietnam People’s Army Department of Military Medicine |
||
| 12 | Thapa, 2007 [33] |
8/2005–10/ 2005. | Nepal | H (in-pt) |
2 | AL, SP | 99 | 53% (AL); 73% (SP) |
>5 yr; (26.5 ± 13.8) |
Yes | Yes | Not reported |
| 13 | Tjitra, 2001 [34] |
2007–2008 | Indonesia | 4 Hs | 2 | ASSP, SP | 105 | 60% | 83.8% (under 12 yr) |
Yes | Yes | Nicholson-Hill Malaria Research Fund & Tudor Foundation. |
| 14 | Trung, 2009 [35] |
NA | Vietnam, |
treatment center (in-pt) |
2 | DHP, AMPQ | 103 | 61.2% | 25.8±13.9 | Yes | Yes | Science and Technology Research Projects of Guangdong Province |
| 15 | Valecha, 2010 [36] |
NA | Multi country (India, Laos, Thailand) | OPD | 2 | DHP, ASMQ | 1150 | 78.4% | mainly adults, (25.46± 13.3) |
Yes | Yes | MMV, Sigma Tau. & Oxford University |
| 16 | van Vgt,2000 [37] |
11/1997-3/1998 | Thailand | H & health camp | 2 | AL, ASMQ |
200 | 73.5% | Adults & children (23, 13–63) |
Wellcome Trust of Great Britain | ||
| 17 | Wilairatana,2002 [38] |
?? | Thailand | H (in-pt) |
2 | DHP, ASMQ |
352 | 66.8% | 24.8 (±13.3) |
No | Yes | Tonghe Phramaceutical Co. Ltd |
AL: Artemether-lumefantrine; AMPQ; artemisinin-piperaquine; ASMQ: artesunate-mefloquine; ASMQh: artesunate-mefloquine home treatment/not supervised; ASMQ2: artesunate-mefloquine 2-day course; ASAQ; artesunate-amodiaquine; ASCQ: artesunate-chloroquine; ASSP: artesunate plus sulfadoxine-pyrimethamine; CQ: chloroquine; DHP: dihydroartemisinin-piperaquine; DHP4: dihydroartemisinin-piperaquine 4-day course; DHPh; dihydroartemisinin-piperaquine home treatment/not supervised; DHPAS dihydroartemisinin-piperaquine & artesunate added; SP: sulfadoxine-pyrimethamine; gr: group(s); H; hospital; In-pt: Inpatients; MMV: Medicines for Malaria Venture; MOST/China: Ministry of Science and Technology of the People’s Republic of China; MSF: Medecins Sans Frontieres; OPD: outpatient department/centre; WHO/RBM: World Health Organization/Roll Back Malaria’ yr: year.